You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the COMBIVENT RESPIMAT (albuterol sulfate; ipratropium bromide) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR COMBIVENT RESPIMAT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for COMBIVENT RESPIMAT

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00400153 ↗ Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD) Completed Boehringer Ingelheim Phase 3 2006-11-01 The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat® inhaler (20 mcg), and COMBIVENT® MDI administered q.i.d on FEV1 at intervals over a treatment period of 12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat® to COMBIVENT® MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 4 to 6 hours will be analyzed. In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.
NCT00818454 ↗ 4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma Completed Boehringer Ingelheim Phase 2 2008-12-01 The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma. In the first cross-over part of the study (Treatment Phases 1 and 2) the marketed product, COMBIVENT CFC MDI will be used. In the second, parallel group part of the trial (Treatment Phase 3) COMBIVENT RESPIMAT will be tested for acute bronchodilator efficacy in a blinded manner at the clinic visits. During the third 4-week treatment phase open label COMBIVENT RESPIMAT will be used for symptom relief as needed.
NCT01019694 ↗ Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease Completed Boehringer Ingelheim Phase 3 2009-11-01 The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler (CFC-MDI) and the free combination of ATROVENT Hydrofluoroalkane (HFA) and albuterol Hydrofluoroalkane (HFA) inhalation aerosols.
NCT01969539 ↗ Ventilator Adapters for Combivent Respimat Terminated Boehringer Ingelheim Phase 4 2013-10-01 The general aim of this 1-day, open label, non-randomised, trial is to characterize the performance of two adapter devices designed to permit use of the Respimat® inhaler with patients requiring mechanical ventilation.
NCT02177253 ↗ Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease Completed Boehringer Ingelheim Phase 3 2002-10-01 The primary objective of this study was to compare the long-term (12-week) bronchodilator efficacy and safety of ipratropium bromide / salbutamol combination administered by the Respimat® 40 mcg / 200 mcg (one inhalation q.i.d.) to COMBIVENT Inhalation Aerosol (two inhalations q.i.d.), ipratropium bromide Respimat® (one inhalation q.i.d.) and Placebo formulations of each in patients with Chronic Obstructive Pulmonary Disease (COPD). An additional objective was to show the superiority of Combivent Respimat as compared to ipratropium bromide (40 mcg) Respimat. Steady state pharmacokinetics over one dosing interval following four weeks of therapy were also characterized.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for COMBIVENT RESPIMAT

Condition Name

Condition Name for COMBIVENT RESPIMAT
Intervention Trials
Pulmonary Disease, Chronic Obstructive 4
Asthma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for COMBIVENT RESPIMAT
Intervention Trials
Pulmonary Disease, Chronic Obstructive 4
Lung Diseases 4
Chronic Disease 4
Lung Diseases, Obstructive 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for COMBIVENT RESPIMAT

Trials by Country

Trials by Country for COMBIVENT RESPIMAT
Location Trials
United States 82
Turkey 1
Greece 1
Poland 1
Taiwan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for COMBIVENT RESPIMAT
Location Trials
Texas 4
Georgia 3
South Carolina 3
Washington 3
Alabama 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for COMBIVENT RESPIMAT

Clinical Trial Phase

Clinical Trial Phase for COMBIVENT RESPIMAT
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for COMBIVENT RESPIMAT
Clinical Trial Phase Trials
Completed 4
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for COMBIVENT RESPIMAT

Sponsor Name

Sponsor Name for COMBIVENT RESPIMAT
Sponsor Trials
Boehringer Ingelheim 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for COMBIVENT RESPIMAT
Sponsor Trials
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.